Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: Outcomes of an expanded access program.

Lung Cancer. 2007 Feb;55(2):187-94. Epub 2006 Nov 7.
Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Janne PA; On Behalf of Pemetrexed Expanded Access Program Investigators.
Eli Lilly and Company, Lilly Corporate Center, Drop Code 6831, Indianapolis, IN 46285, United States.

BACKGROUND: An expanded access program (EAP) provided patient access to pemetrexed prior to its commercial availability. The current report consists of US patients in the EAP who had chemotherapy naive pleural mesothelioma.

METHODS: Eligible patients had a histologic or cytologic diagnosis of malignant mesothelioma that was not amenable to curative treatment with mesothelioma surgery. Study treatment consisted of pemetrexed 500mg/m(2) in combination with cisplatin 75mg/m(2) once every 21 days. Vitamin B12, folic acid, and dexamethasone were administered as prophylaxis. Serious adverse events (SAEs) were reported by investigators and compiled in a pharmacovigilance database for all patients enrolled in the EAP.

RESULTS: Of 1056 patients receiving at least one dose of pemetrexed in the EAP, 728 had chemotherapy naive pleural mesothelioma. Median age of this group was 70 years (range 23-89 years) and 84% were male. Among 615 patients, overall response rate was 20.5%, including 12 complete responses (2.0%) and 114 partial responses (18.5%). An additional 290 patients (47.2%) had stable disease. Median survival rate for all 728 patients was 10.8 months (95% CI=9.8, 12.3; 60.3% censorship) and 1 year survival was 45.4%. The most commonly reported SAEs in the overall EAP irrespective of causality were dehydration (7.2%), nausea (5.2%), vomiting (4.9%), dyspnea (3.8%), and pulmonary embolism (2.4%).

CONCLUSIONS: In this large cohort, 67.7% of patients treated with first-line chemotherapy experienced a response or stable disease. Survival time and toxicity from this EAP were promising for this difficult-to-treat disease.

Source

PMID: 17092602 [PubMed - in process]
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.

Free Mesothelioma Information Packet

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

Yes   No

Mesothelioma Mesothelioma Treatment
Conventional Therapies Alternative Treatments Experimental Therapies Treatment by Stage Mesothelioma Doctors Mesothelioma Experts Clinical Trials Mesothelioma Clinics Ask Your Doctor Caregivers and the Aging Mesothelioma Research Review Studies Case Studies Etiological Studies Diagnostic Studies Therapy Studies Mesothelioma Resources Counseling Resources Mesothelioma Treatment Alerts
Asbestos Cancer Asbestos Exposure Mesothelioma News Veterans & Mesothelioma Mesothelioma Attorney FREE Case Evaluation Top Mesothelioma Doctors

Harvey Pass, M.D.
Dr. Harvey Pass is a top mesothelioma doctor and expert in the diagnosis and treatment of pleural mesothelioma, a type of lung cancer that is often related to asbestos exposure.

Eric Vallieres, M.D.
Dr. Eric Vallieres is the Surgical Director at the Swedish Cancer Institute in Seattle, Washington specializing in thoracic surgery and mesothelima.

David Rice, M.D.
Dr. David Rice is an Associate Professor and Assistant Surgeon at The University of Texas M.D. Anderson Cancer Center where he serves as the director of the Minimally Invasive Surgery and Mesothelioma programs.

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here.